EL7.AI
Stocks•16 July 2026•
1 min read

Senzime Narrows Q2 Losses Despite Slight Revenue Dip

Key Facts

1Net sales amounted to TSEK 24,671 in Q2 2026, a 4% decrease compared to the previous year.
2Gross margin before depreciation improved to 65.7% compared to 61.8% in the previous year.
3Earnings per share improved to a loss of SEK -0.14 compared to a loss of SEK -0.24 in the same quarter last year.

Amid a sector-wide push for operational efficiency, Swedish medical device maker Senzime reported Q2 2026 results characterized by improved profitability despite sales pressure. According to reports, net sales reached TSEK 24,671, representing a 4% decrease year-over-year. However, the company successfully narrowed its loss per share to SEK -0.14 from SEK -0.24 in the prior year's quarter, bolstered by a significant rise in gross margin before depreciation to 65.7%.

This performance comes as the med-tech industry navigates mixed global demand, with strong momentum in TetraGraph sensor sales helping to offset headwinds in the U.S. monitor market. Compared to peers in the patient monitoring space, such as Masimo which has also prioritized margin expansion, Senzime’s results reflect the impact of disciplined cost-cutting measures. Per market data, the improvement in gross margins from 61.8% to 65.7% strengthens the company's resilience against the supply chain fluctuations that have recently impacted the sector.

Looking ahead, investors are focusing on management's ability to restore top-line growth while maintaining elevated margin levels. market demand. Global markets are also awaiting the U.S. Monetary Policy Report on July 10, 2026, which could influence financing costs for growth-oriented healthcare firms.